GSM Treatment Algorithm: Every Line of Therapy for Genitourinary Syndrome of Menopause

Import from '@/components'

What Is GSM and How Is It Diagnosed?

GSM is the umbrella term that replaced "vulvovaginal atrophy" and "atrophic vaginitis" in 2014, because those older names missed the urinary component entirely. Low estrogen after menopause, or after any cause of hypoestrogenism, depletes collagen and glycogen in vaginal, vulvar, and lower urinary tract tissue. The result is a cluster of symptoms that does not improve on its own and typically worsens over time without treatment.

Symptoms That Define GSM

The 2023 Menopause Society (NAMS) Clinical Practice Statement on GSM organizes symptoms into three domains:

• Vaginal and vulvar: dryness, burning, irritation, discharge, decreased lubrication during sex
• Sexual: dyspareunia (pain with penetration), reduced arousal, difficulty reaching orgasm, post-coital bleeding
• Urinary: urgency, frequency, recurrent urinary tract infections, dysuria, stress or urge incontinence

Symptoms in the urinary domain are frequently attributed to other causes, which delays diagnosis by years.

How a Clinician Diagnoses GSM

Diagnosis is clinical. A pelvic exam typically shows pale, dry, or friable vaginal walls, loss of rugae, narrowing of the introitus, and urethral caruncle. Vaginal pH above 5.0 supports the diagnosis. A vaginal maturation index (VMI) showing a shift from superficial to parabasal cells confirms hypoestrogenism at the tissue level, though VMI is used more often in research than in routine practice. No blood test is required: estradiol levels correlate poorly with tissue symptoms.

Life Stages When GSM Appears

Perimenopausal women often notice early dryness and recurrent UTIs two to three years before their final period, as estrogen begins to fluctuate downward. Postmenopausal women carry the heaviest symptom burden. Women with premature ovarian insufficiency (POI) before age 40, those on aromatase inhibitors for breast cancer, and those on GnRH agonists for endometriosis or fibroids face the same estrogen-depleted tissue changes, often more abruptly.

First-Line Therapy: Non-Hormonal Vaginal Products

For women with mild symptoms, or for any woman who prefers to avoid hormones, non-hormonal vaginal moisturizers and lubricants are the first clinical step. They do not restore vaginal epithelium the way estrogen does, but they relieve discomfort reliably when used correctly.

Vaginal Moisturizers

Moisturizers are designed for regular use, not just during sex. Products containing polycarbophil or hyaluronic acid reduce vaginal pH, improve moisture, and relieve itching and burning. The key is consistency: three to five times per week is a typical recommended frequency. A 2022 JAMA Internal Medicine randomized trial (N=302) found that a vaginal moisturizer containing hyaluronic acid was non-inferior to low-dose vaginal estradiol cream for reducing the most bothersome symptom score at 12 weeks, though the estrogen arm showed greater improvement in VMI. This result matters because it gives women with contraindications to estrogen a rigorously tested alternative.

Lubricants

Lubricants are used at the time of sexual activity. Water-based and silicone-based products are both appropriate. Oil-based lubricants degrade latex condoms. Avoid products containing glycerin, fragrances, or warming agents, which can irritate already sensitive tissue.

Pelvic Floor Physical Therapy

For women whose dyspareunia has a musculoskeletal component, including vaginismus or hypertonic pelvic floor dysfunction that developed in response to pain, pelvic floor physical therapy is an evidence-supported adjunct. It does not treat the mucosal deficit, but it addresses pain-guarding patterns that persist even after the tissue heals.

Second-Line Therapy: Local (Vaginal) Hormonal Treatments

When non-hormonal approaches do not adequately control symptoms, or when symptoms are moderate to severe at diagnosis, low-dose local estrogen is the most effective treatment with the best evidence base. The Menopause Society, ACOG, and the British Menopause Society all recommend it as a primary treatment for GSM isolated to the genitourinary tract.

Why "Local" Matters

Low-dose vaginal estrogen products deliver estrogen directly to the target tissue. Systemic absorption is low enough that serum estradiol levels generally remain within the postmenopausal range (<20 pg/mL) for most marketed products, particularly the 10-mcg vaginal tablet and the estradiol vaginal ring (Estring). This low systemic exposure is why major guidelines do not require routine endometrial surveillance or progestogen co-administration when using these low-dose local formulations in women with an intact uterus.

Available Local Estrogen Formulations

| Product | Estrogen | Dose | Frequency after loading | |---|---|---|---| | Vaginal cream (Estrace, generics) | Estradiol | 0.5-2 g (2-100 mcg estradiol) | 1-3x/week | | Vaginal tablet (Vagifem, Yuvafem) | Estradiol 10 mcg | 1 tablet | 2x/week | | Vaginal suppository (Imvexxy) | Estradiol 4 or 10 mcg | 1 suppository | 2x/week | | Vaginal ring (Estring) | Estradiol | 7.5 mcg/day | Replace every 90 days | | Conjugated estrogen cream (Premarin vaginal) | Conjugated equine estrogens | 0.5-2 g | 2x/week |

ACOG's 2022 Clinical Practice Advisory on GSM states that all of these formulations are effective and that choice should be guided by patient preference, cost, and ease of use.

Intravaginal DHEA (Prasterone / Intrarosa)

Prasterone is a vaginal suppository of dehydroepiandrosterone (DHEA), 6.5 mg, inserted once daily. Inside vaginal cells, DHEA converts locally to both estrogens and androgens. The AMETHYST trial (N=464) demonstrated significant improvement in dyspareunia severity, vaginal dryness, and VMI at 12 weeks compared with placebo, with minimal systemic sex-steroid elevation. For women who want a non-estrogen label on their prescription, prasterone is a distinct mechanism option that the FDA approved in 2016.

Ospemifene: The Oral Non-Estrogen Option

Ospemifene 60 mg orally once daily is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in vaginal tissue and as an antagonist or neutral agent in breast tissue. It is the only oral prescription drug approved specifically for moderate to severe dyspareunia and vaginal dryness from GSM. The STAR-1, STAR-2, and STAR-3 trials showed significant improvements in VMI, vaginal pH, and most bothersome symptom compared with placebo over 12 weeks. Women who dislike intravaginal products, or who have difficulty with application, often prefer this route.

Ospemifene has a black-box warning for endometrial effects with long-term use and should not be used in women with known or suspected estrogen-dependent cancers or unexplained uterine bleeding. It may increase hot flash frequency in some women.

Third-Line Therapy: Systemic Hormone Therapy

Systemic estrogen-progestogen therapy (or estrogen alone in women without a uterus) is not the first choice for GSM in isolation. It carries more systemic exposure and a different risk profile than local therapy. However, for women who need treatment for both bothersome vasomotor symptoms (hot flashes, night sweats) and GSM, systemic hormone therapy addresses both simultaneously. Adding a low-dose local estrogen to systemic therapy is also appropriate if genital symptoms persist.

Who Benefits from Systemic HRT for GSM

• Women with moderate to severe hot flashes or night sweats alongside GSM
• Women under age 60 or within 10 years of menopause, who are within the Menopause Society "timing hypothesis" window where cardiovascular risk is lowest
• Women with POI, who need hormone replacement for bone, cardiovascular, and cognitive protection, not just symptom relief

The WomanRx GSM Therapy Selection Framework organizes decision-making into four clinical questions before selecting a line of therapy:

1. Are symptoms isolated to the genitourinary tract, or does the woman also have systemic menopause symptoms (vasomotor, sleep, mood)?
2. Does she have a personal or family history of hormone-sensitive cancer, VTE, or cardiovascular disease that changes the risk calculus?
3. What is her preference regarding route of administration (vaginal, oral, transdermal, or systemic)?
4. Is she in perimenopause, postmenopause, medically induced menopause, or POI, since these states carry different baseline risk profiles and hormone-replacement goals?

Answering these four questions before prescribing prevents the common clinical error of treating a 42-year-old woman with POI with a vaginal tablet alone, when she also needs systemic replacement for bone density and cardiovascular protection.

Pregnancy and Lactation Safety

Vaginal estrogen is contraindicated in pregnancy. Any estrogen product, including low-dose topical formulations, carries a theoretical risk to the fetus, and GSM symptoms by definition occur in a hypoestrogenic state that does not coexist with normal pregnancy. A woman who develops vaginal dryness or dyspareunia while pregnant or postpartum is experiencing a different physiological state than GSM, and treatment differs accordingly.

Postpartum and lactation: Breastfeeding drops estradiol markedly and can cause vaginal dryness and dyspareunia identical to GSM symptoms. This is sometimes called lactational atrophy. Non-hormonal lubricants and moisturizers are the safest first approach during lactation. Low-dose vaginal estrogen is sometimes prescribed off-label in this setting, but systemic absorption data in lactating women are limited, and most clinicians prefer to wait until weaning if possible. Ospemifene and prasterone have no safety data in pregnancy or lactation and should not be used.

Contraception: Women in perimenopause who still have any possibility of ovulation must use contraception if they do not want to conceive, regardless of whether they are using local estrogen for GSM. Local vaginal estrogen is not a contraceptive.

Emerging and Adjunct Therapies

Energy-Based Devices (Laser and Radiofrequency)

Fractional CO2 laser and microablative radiofrequency devices have been marketed aggressively for GSM. The mechanism proposed is thermal stimulation of collagen remodeling in vaginal tissue. Early observational data were encouraging, but the only sham-controlled randomized trial published to date (N=78, JAMA 2021) found no significant difference between fractional CO2 laser and sham treatment for dyspareunia or vaginal dryness at 12 months. The FDA has warned against marketing these devices for vaginal rejuvenation without cleared indications. Laser may still have a role for women with absolute contraindications to all hormonal options, but it should be offered only as part of a shared decision-making conversation that includes this sham-controlled trial result.

Testosterone (Off-Label)

Topical testosterone is not FDA-approved for GSM, but some women's-health specialists prescribe compounded preparations for dyspareunia and reduced genital sensitivity, particularly when androgen deficiency is suspected. Evidence is thin. The 2019 Global Consensus Statement on Testosterone in Women supports testosterone only for hypoactive sexual desire disorder (HSDD), not specifically for GSM. Use remains off-label and should be clearly discussed with patients.

Vaginal Oxytocin

Intranasal and vaginal oxytocin preparations have shown modest benefits for vaginal dryness in small trials, but no large randomized controlled trial has confirmed efficacy sufficient to recommend routine use.

Who This Treatment Is Right For, by Life Stage

Perimenopause (40s to Early 50s)

Estrogen fluctuates rather than disappears. Vaginal dryness may be intermittent. Non-hormonal moisturizers and lubricants often suffice. If symptoms are significant, low-dose local estrogen is appropriate. Contraception remains necessary if pregnancy is not desired.

Early Postmenopause (Within 10 Years of Final Period)

This is the highest-need window. Symptoms are often moderate to severe and worsening. All three lines of therapy apply. Women in this window who also have vasomotor symptoms are good candidates for systemic HRT, which addresses both. The Menopause Society notes that the benefit-risk ratio of systemic HRT is most favorable in this window for most healthy women.

Late Postmenopause (More Than 10 Years from Final Period, or Over 60)

Local therapy remains appropriate and effective regardless of time since menopause. Initiating systemic HRT more than 10 years after menopause or after age 60 requires more individualized risk assessment because of cardiovascular and VTE data from the Women's Health Initiative Memory Study and WHI extension analyses. Local estrogen does not share those systemic risks.

Premature Ovarian Insufficiency (POI, Before Age 40)

Women with POI should receive systemic hormone replacement, not just local therapy, until at least the average age of natural menopause (51 years), for bone, cardiovascular, and neurological protection. GSM symptoms in this group are a secondary indication that systemic replacement also addresses. The ACOG Committee Opinion on POI explicitly supports hormone therapy continuation to age 51 absent specific contraindications.

Women on Aromatase Inhibitors for Breast Cancer

This group faces some of the most severe GSM, because aromatase inhibitors suppress estrogen to near-zero. Systemic estrogen is contraindicated. Vaginal estrogen in this group has been debated, but the REJOICE trial (N=302) and subsequent analyses suggest systemic absorption from low-dose vaginal estradiol (10 mcg tablet) remains below levels associated with recurrence risk. The 2023 NAMS position statement states that vaginal prasterone and ospemifene are alternative options for this group, with the caveat that long-term oncologic safety data remain limited. Non-hormonal options should be tried first. Decisions in this group require oncology coordination.

The Evidence Gap: What We Still Do Not Know

Women have been consistently underrepresented in GSM trials on several dimensions. Most major trials enrolled women with intact ovaries transitioning through natural menopause, aged 55 to 65. Data specific to women with POI, women on GnRH agonists for fibroids or endometriosis, and perimenopausal women with fluctuating rather than absent estrogen are sparse. The best-studied formulations (10-mcg vaginal tablet, Estring ring) are also among the oldest; newer compounded "bioidentical" low-dose estrogen products carry essentially no randomized trial data despite widespread prescribing.

As The Menopause Society's 2023 statement notes: "The evidence base for managing GSM in women with breast cancer or other hormone-sensitive conditions remains insufficient to make definitive recommendations, and individualized care guided by oncology is required." Citing that directly reflects where the science actually sits.

Starting Treatment: A Practical Checklist

Before initiating any GSM therapy, review these steps with your clinician:

1. Confirm the diagnosis clinically. Rule out infection, dermatosis (lichen sclerosus, lichen planus), or contact dermatitis, which require different treatments.
2. Identify your most bothersome symptom. Dyspareunia, dryness, and urinary urgency may not all respond equally to the same first agent.
3. Establish your contraindications. History of hormone-sensitive cancer, unexplained vaginal bleeding, VTE, or active liver disease alters which options are available.
4. Set a 12-week reassessment date. Tissue response to vaginal estrogen takes 8 to 12 weeks for full effect. Stopping at 4 weeks because of impatience is among the most common reasons women cycle through therapies unnecessarily.
5. Plan for long-term use. GSM is a chronic condition. Unlike vasomotor symptoms, which may resolve, GSM symptoms return within weeks of stopping treatment. Maintenance therapy is the rule, not the exception.

A vaginal pH of 5.0 or below after 12 weeks of low-dose vaginal estrogen is a useful objective marker that treatment is working at the tissue level, even before symptoms fully resolve.